AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02905318
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125 mg orally on days 1-21 each 28 day cycle
Trial: NCT02684669
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active drug infusion
Trial: NCT00393770
Drug: L-acetylcarnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250-500 mg/kg/die.
Trial: NCT02624349
Drug: Quadravalent human papillomavirus vaccine
RxNorm normalized name: human papillomavirus
DrugBank: Human papillomavirus type 6 L1 capsid protein antigen (DB10299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
Trial: NCT00962156
Drug: Ringers acetate
RxNorm normalized name: Mimulus ringens whole extract
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion for volume expansion in the ICU
Trial: NCT04048278
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
Trial: NCT02044965
Drug: Probiotic
RxNorm normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
Trial: NCT00247130
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00247130
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04428502
Drug: Enbrel
RxNorm normalized name: Enbrel
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT01262352
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg tablet, oral use, twice daily every 12 hours (q12h)
Trial: NCT02235727
Drug: GBR 900
RxNorm normalized name: GBR-12783
DrugBank: GBR-12783 (DB17027)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02036554
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Trial: NCT02036554
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Trial: NCT02447705
Drug: telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: telbivudine replace Lamivudine
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral drinking solution
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral drinking solution
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral drinking solution
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral drinking solution
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral drinking solution
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral drinking solution
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral drinking solution
Trial: NCT00035347
Drug: ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gram once daily for 2 to 5 days
Trial: NCT00035347
Drug: IV levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg once daily
Trial: NCT00035347
Drug: oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg once daily
Trial: NCT04144465
Drug: NORADRENALIN
RxNorm normalized name: Noradrenaline
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
Trial: NCT04144465
Drug: PHENYLEPHRINE
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral drinking solution
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral drinking solution
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,0 mg immediate release tablet
Trial: NCT01145014
Drug: BI 660848
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,0 mg immediate release tablet
Trial: NCT03459599
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week
Trial: NCT00450658
Drug: HZT-501
RxNorm normalized name: HZT-501
DrugBank: HZT-501 (DB05369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
Trial: NCT02975934
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rucaparib will be administered daily.
Trial: NCT02975934
Drug: Abiraterone acetate or Enzalutamide or Docetaxel
RxNorm normalized name: chlorhexidine acetate Medicated Pad or Tape
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
Trial: NCT01480154
Drug: Akt Inhibitor MK2206
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01480154
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00001860
Drug: Sandostatin LAR Depot versus transsphenoidal surgery
RxNorm normalized name: octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00327470
Drug: Pegaptanib Sodium 0.3 mg
RxNorm normalized name: pegaptanib sodium 0.3 mg/90 microliter (0.09 mL) INTRAOCULR SYRINGE (ML)
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegaptanib Sodium dosed every 6 weeks in affected eye.
Trial: NCT00328978
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00349531
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01165567
Drug: sarpogrelate
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarpogrelate, 300mg/day,duration: 4 weeks
Trial: NCT01399424
Drug: CP
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunization
Trial: NCT01690338
Drug: Vecuronium Bromide
RxNorm normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
Trial: NCT01690338
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
Trial: NCT01690338
Drug: Cisatracurium
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
Trial: NCT00712491
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three subconjunctival injections of 1320 micrograms sirolimus each.
Trial: NCT00712491
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three intravitreal injections of 352 micrograms sirolimus each.
Trial: NCT03810742
Drug: Nanoliposomal Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
Trial: NCT00826722
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg tablet
Trial: NCT05301712
Drug: Naloxone hydrochloride 5.0mg/5ml
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Initial dose: 4mg, Intravenous injection~* Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4mg+8mg/day\*7=60mg
Trial: NCT02509104
Drug: FDC capsule of dutasteride and tamsulosin
RxNorm normalized name: tamsulosin and dutasteride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
Trial: NCT02509104
Drug: Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
RxNorm normalized name: tamsulosin and dutasteride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
Trial: NCT01667081
Drug: Grazoprevir
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
Trial: NCT05301712
Drug: Sodium Chloride 45mg/5ml
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Initial dose: 4ml, Intravenous injection~* Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4ml+8ml/day\*7=60ml
Trial: NCT01744574
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
Trial: NCT03746652
Drug: Daratumumab, Ixazomib, Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
Trial: NCT04302896
Drug: dolutegravir oral tablet 50mg
RxNorm normalized name: dolutegravir Oral Tablet
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tivicay® (dolutegravir, DTG), a HIV-1 integrase strand transfer inhibitor (INSTI), is FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 30kg. Tivicay® 50mg tablets \[GlaxoSmithKline\] are yellow, round, film-coated, biconvex tablets debossed with SV 572 on one side and 50 on the other side. The inactive ingredients in each tablet are D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide.
Trial: NCT04302896
Drug: emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Descovy® (emtricitabine/tenofovir alafenamide, FTC/TAF) is a combination of two HIV nucleoside analog reverse transcriptase inhibitors (NRTIs) FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg. Descovy® 200 mg/25 mg tablets \[Gilead\] are blue, rectangular-shaped, and film-coated with GSI debossed on one side and 225 on the other side. The inactive ingredients are croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
Trial: NCT01337609
Drug: Ganeden BC30
RxNorm normalized name: Ganedenbc 30
DrugBank: Bacillus coagulans (DB19246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 billion CFU per capsule; One pill daily for 60 days
Trial: NCT00122733
Drug: loxapine
RxNorm normalized name: Loxapine
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00579085
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Ketamine .35mg/kg times ten days.
Trial: NCT00291330
Drug: dabigatran etexilate 150 mg
RxNorm normalized name: dabigatran etexilate 150 MG
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT00291330
Drug: warfarin (INR 2-3)
RxNorm normalized name: warfarin sodium 3 MG
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prn to maintain INR (2-3)
Trial: NCT01412073
Drug: oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
Trial: NCT01412073
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby \& the placenta
Trial: NCT03989037
Drug: Herceptin
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
Trial: NCT03989037
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
Trial: NCT03989037
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
Trial: NCT03669367
Drug: Abatacept Injection
RxNorm normalized name: abatacept Injection
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
Trial: NCT01689740
Drug: Active Placebo Dose MDMA-assisted therapy (25 mg)
RxNorm normalized name: Activated natural killer cell therapy
DrugBank: Activated natural killer cell therapy (DB17172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 25 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 12.5 mg 1.5 to 2.5 hours later.
Trial: NCT02808182
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
Trial: NCT03963401
Drug: PF-06700841
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
Trial: NCT04562766
Drug: Rilzabrutinib
RxNorm normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg Caplet
Trial: NCT04142788
Drug: Patiromer
RxNorm normalized name: Patiromer
DrugBank: Patiromer (DB09263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
Trial: NCT02878538
Drug: Deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
Trial: NCT03270020
Drug: Denosumab 70 MG/ML [Xgeva]
RxNorm normalized name: denosumab 70 MG/ML [Xgeva]
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As already described in arm description
Trial: NCT04179474
Drug: Ubrogepant
RxNorm normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].
Trial: NCT04179474
Drug: Erenumab
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].
Trial: NCT00821327
Drug: Gemcitabine, Cisplatin, Sunitinib
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity.
Trial: NCT02942576
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.
Trial: NCT01069120
Drug: Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2, 25 mg capsules once per day
Trial: NCT01069120
Drug: Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 25 mg capsule once per day
Trial: NCT04179474
Drug: Galcanezumab
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 SC injections of galcanezumab 120 mg \[Intervention C\].
Trial: NCT01066039
Drug: Bisoprolol
RxNorm normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.